Inhibition of HIF1α Signaling: A Grand Slam for MDS Therapy?

Jiahao Chen, Ulrich G. Steidl

Research output: Contribution to journalArticle

Abstract

The recent focus on genomics in myelodysplastic syndromes (MDS) has led to important insights and revealed a daunting genetic heterogeneity, which is presenting great challenges for clinical treatment and precision oncology approaches in MDS. Hayashi and colleagues show that multiple mutations frequently found in MDS activate HIF1α signaling, which they also found to be sufficient to induce overt MDS in mice. Furthermore, both genetic and pharmacologic inhibition of HIF1α suppressed MDS development with only mild effects on normal hematopoiesis, implicating HIF1α signaling as a promising therapeutic target to tackle the heterogeneity of MDS. Cancer Discov; 8(11); 1355-7.

Original languageEnglish (US)
Pages (from-to)1355-1357
Number of pages3
JournalCancer Discovery
Volume8
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Myelodysplastic Syndromes
Therapeutics
Genetic Heterogeneity
Hematopoiesis
Genomics
Mutation
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Inhibition of HIF1α Signaling : A Grand Slam for MDS Therapy? / Chen, Jiahao; Steidl, Ulrich G.

In: Cancer Discovery, Vol. 8, No. 11, 01.11.2018, p. 1355-1357.

Research output: Contribution to journalArticle

@article{f13e6bf7c629435f954fda3ef7d7eedf,
title = "Inhibition of HIF1α Signaling: A Grand Slam for MDS Therapy?",
abstract = "The recent focus on genomics in myelodysplastic syndromes (MDS) has led to important insights and revealed a daunting genetic heterogeneity, which is presenting great challenges for clinical treatment and precision oncology approaches in MDS. Hayashi and colleagues show that multiple mutations frequently found in MDS activate HIF1α signaling, which they also found to be sufficient to induce overt MDS in mice. Furthermore, both genetic and pharmacologic inhibition of HIF1α suppressed MDS development with only mild effects on normal hematopoiesis, implicating HIF1α signaling as a promising therapeutic target to tackle the heterogeneity of MDS. Cancer Discov; 8(11); 1355-7.",
author = "Jiahao Chen and Steidl, {Ulrich G.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1158/2159-8290.CD-18-1061",
language = "English (US)",
volume = "8",
pages = "1355--1357",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Inhibition of HIF1α Signaling

T2 - A Grand Slam for MDS Therapy?

AU - Chen, Jiahao

AU - Steidl, Ulrich G.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The recent focus on genomics in myelodysplastic syndromes (MDS) has led to important insights and revealed a daunting genetic heterogeneity, which is presenting great challenges for clinical treatment and precision oncology approaches in MDS. Hayashi and colleagues show that multiple mutations frequently found in MDS activate HIF1α signaling, which they also found to be sufficient to induce overt MDS in mice. Furthermore, both genetic and pharmacologic inhibition of HIF1α suppressed MDS development with only mild effects on normal hematopoiesis, implicating HIF1α signaling as a promising therapeutic target to tackle the heterogeneity of MDS. Cancer Discov; 8(11); 1355-7.

AB - The recent focus on genomics in myelodysplastic syndromes (MDS) has led to important insights and revealed a daunting genetic heterogeneity, which is presenting great challenges for clinical treatment and precision oncology approaches in MDS. Hayashi and colleagues show that multiple mutations frequently found in MDS activate HIF1α signaling, which they also found to be sufficient to induce overt MDS in mice. Furthermore, both genetic and pharmacologic inhibition of HIF1α suppressed MDS development with only mild effects on normal hematopoiesis, implicating HIF1α signaling as a promising therapeutic target to tackle the heterogeneity of MDS. Cancer Discov; 8(11); 1355-7.

UR - http://www.scopus.com/inward/record.url?scp=85055911333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055911333&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-18-1061

DO - 10.1158/2159-8290.CD-18-1061

M3 - Article

C2 - 30385524

AN - SCOPUS:85055911333

VL - 8

SP - 1355

EP - 1357

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 11

ER -